News Topical, Digital Desk : More than 100 million people in India suffer from diabetes, of which approximately 1 million suffer from type 1 diabetes, which requires the most insulin. Insulin is needed for the treatment of both type 1 and type 2 diabetes patients. Diabetes is the fastest-growing disease in India, posing a major concern for the country. People suffering from type 1 diabetes urgently need insulin. Insulin is used to control the blood sugar levels of diabetic patients. We all know that insulin is injected into the body of diabetic patients through injections, which controls or balances the sugar levels of diabetics. Modifying this injectable process, Cipla, a renowned pharmaceutical company, has announced the launch of inhaled insulin, which now allows insulin to be delivered to the patient's body through breathing.
Cipla to launch inhaled insulin in India
Cipla, a renowned pharmaceutical company, has taken a significant step for diabetes patients in India. It has made a significant change in the process of administering insulin for diabetes treatment, which was previously administered through injections, and has announced the launch of a rapid-acting inhaled insulin powder called 'Afrezza' in the Indian market, which will provide relief to patients who avoid or fear injections or needles. Now, people suffering from diabetes can simply inhale the insulin powder and deliver it to their bodies through their breath.
The company received approval
The company stated that it received approval for its rapid-acting inhaled insulin powder from the government pharmaceutical agency, the Central Drugs Standard Control Organization (CDSCO), last year, allowing it to quickly introduce and promote this new type of insulin in the Indian market. According to the company, this insulin shows rapid effectiveness in diabetes patients.
How is inhaled insulin used?
Afrezza, a rapid-acting inhaled insulin powder, can be used from a special single-use cartridge via a small inhaler. You can inhale your dose directly into the body by inhaling it according to the quantity of insulin prescribed by your doctor. According to Cipla's Global Chief Director, this new insulin will save people from the painful process of daily injections.
--Advertisement--
Share



